Abstract

Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor–platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.

REFERENCES

REFERENCES
1.
Joly
BS
,
Coppo
P
,
Veyradier
A
.
Thrombotic thrombocytopenic purpura
.
Blood
.
2017
;
129
(
21
):
2836
-
2846
.
2.
Rock
GA
,
Shumak
KH
,
Buskard
NA
, et al
; Canadian Apheresis Study Group.
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura
.
N Engl J Med
.
1991
;
325
(
6
):
393
-
397
.
3.
Froissart
A
,
Veyradier
A
,
Hié
M
,
Benhamou
Y
,
Coppo
P
; French Reference Center for Thrombotic Microangiopathies.
Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story
.
Eur J Intern Med
.
2015
;
26
(
9
):
659
-
665
.
4.
Peyvandi
F
,
Scully
M
,
Kremer Hovinga
JA
, et al
; TITAN Investigators.
Caplacizumab for acquired thrombotic thrombocytopenic purpura
.
N Engl J Med
.
2016
;
374
(
6
):
511
-
522
.
5.
Scully
M
,
Cataland
SR
,
Peyvandi
F
, et al
; HERCULES Investigators.
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
.
N Engl J Med
.
2019
;
380
(
4
):
335
-
346
.
6.
Scully
M
,
Hunt
BJ
,
Benjamin
S
, et al
; British Committee for Standards in Haematology.
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
.
Br J Haematol
.
2012
;
158
(
3
):
323
-
335
.
7.
George
JN
.
Clinical practice. Thrombotic thrombocytopenic purpura
.
N Engl J Med
.
2006
;
354
(
18
):
1927
-
1935
.
8.
Bendapudi
PK
,
Hurwitz
S
,
Fry
A
, et al
.
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
.
Lancet Haematol
.
2017
;
4
(
4
):
e157
-
e164
.
9.
Li
A
,
Khalighi
PR
,
Wu
Q
,
Garcia
DA
.
External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment
.
J Thromb Haemost
.
2018
;
16
(
1
):
164
-
169
.
10.
Bell
WR
,
Braine
HG
,
Ness
PM
,
Kickler
TS
.
Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients
.
N Engl J Med
.
1991
;
325
(
6
):
398
-
403
.
11.
Cataland
SR
,
Kourlas
PJ
,
Yang
S
, et al
.
Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura
.
Blood Adv
.
2017
;
1
(
23
):
2075
-
2082
.
12.
Schwartz
J
,
Padmanabhan
A
,
Aqui
N
, et al
.
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: the Seventh Special Issue
.
J Clin Apher
.
2016
;
31
(
3
):
149
-
162
.
13.
Scully
M
,
Cataland
S
,
Coppo
P
, et al
; International Working Group for Thrombotic Thrombocytopenic Purpura.
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
.
J Thromb Haemost
.
2017
;
15
(
2
):
312
-
322
.
14.
Patriquin
CJ
,
Clark
WF
,
Pavenski
K
,
Arnold
DM
,
Rock
G
,
Foley
SR
; Canadian Apheresis Group.
How we treat thrombotic thrombocytopenic purpura: results of a Canadian TTP practice survey
.
J Clin Apher
.
2017
;
32
(
4
):
246
-
256
.
15.
Mazepa
MA
,
Raval
JS
,
Brecher
ME
,
Park
YA
.
Treatment of acquired thrombotic thrombocytopenic purpura in the U.S. remains heterogeneous: current and future points of clinical equipoise
.
J Clin Apher
.
2018
;
33
(
3
):
291
-
296
.
16.
Sadler
JE
,
Muia
J
,
Dolatshahi
L
, et al
Efficacy of adjuvant low dose rituximab and plasma exchange for acquired TTP with severe ADAMTS13 deficiency — results of the ART Study [abstract]. Blood.
2018
;132(suppl 1). Abstract 374.
17.
Page
EE
,
Kremer Hovinga
JA
,
Terrell
DR
,
Vesely
SK
,
George
JN
.
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura
.
Blood
.
2016
;
127
(
24
):
3092
-
3094
.
18.
Jin
M
,
Casper
TC
,
Cataland
SR
, et al
.
Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
.
Br J Haematol
.
2008
;
141
(
5
):
651
-
658
.
19.
Peyvandi
F
,
Lavoretano
S
,
Palla
R
, et al
.
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission
.
Haematologica
.
2008
;
93
(
2
):
232
-
239
.
20.
Chemnitz
J
,
Draube
A
,
Scheid
C
, et al
.
Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab
.
Am J Hematol
.
2002
;
71
(
2
):
105
-
108
.
21.
Scully
M
,
Cohen
H
,
Cavenagh
J
, et al
.
Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13
.
Br J Haematol
.
2007
;
136
(
3
):
451
-
461
.
22.
Clark
WF
,
Rock
G
,
Barth
D
, et al
; members of Canadian Apheresis Group.
A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab
.
Br J Haematol
.
2015
;
170
(
2
):
208
-
217
.
23.
Page
EE
,
Kremer Hovinga
JA
,
Terrell
DR
,
Vesely
SK
,
George
JN
.
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015
.
Blood Adv
.
2017
;
1
(
10
):
590
-
600
.
24.
Froissart
A
,
Buffet
M
,
Veyradier
A
, et al
; Experience of the French Thrombotic Microangiopathies Reference Center.
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange
.
Crit Care Med
.
2012
;
40
(
1
):
104
-
111
.
25.
Scully
M
,
McDonald
V
,
Cavenagh
J
, et al
.
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
.
Blood
.
2011
;
118
(
7
):
1746
-
1753
.
26.
Westwood
JP
,
Webster
H
,
McGuckin
S
,
McDonald
V
,
Machin
SJ
,
Scully
M
.
Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
.
J Thromb Haemost
.
2013
;
11
(
3
):
481
-
490
.
27.
Hie
M
,
Gay
J
,
Galicier
L
, et al
; French Thrombotic Microangiopathies Reference Centre.
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
.
Blood
.
2014
;
124
(
2
):
204
-
210
.
28.
Westwood
JP
,
Thomas
M
,
Alwan
F
, et al
.
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens
.
Blood Adv
.
2017
;
1
(
15
):
1159
-
1166
.
29.
Jestin
M
,
Benhamou
Y
,
Schelpe
AS
, et al
; French Thrombotic Microangiopathies Reference Center.
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
.
Blood
.
2018
;
132
(
20
):
2143
-
2153
.
30.
Zaja
F
,
Battista
ML
,
Pirrotta
MT
, et al
.
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
.
Haematologica
.
2008
;
93
(
6
):
930
-
933
.
31.
US Food and Drug Administration
.
FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder
. .
32.
Benhamou
Y
,
Boelle
PY
,
Baudin
B
, et al
; Experience of the French Thrombotic Microangiopathies Reference Center.
Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2015
;
13
(
2
):
293
-
302
.
33.
Benhamou
Y
,
Assié
C
,
Boelle
PY
, et al
; Thrombotic Microangiopathies Reference Center.
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience
.
Haematologica
.
2012
;
97
(
8
):
1181
-
1186
.
34.
Page
EE
,
Kremer Hovinga
JA
,
Terrell
DR
,
Vesely
SK
,
George
JN
.
Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura
.
Blood
.
2016
;
128
(
17
):
2175
-
2178
.
35.
Eskazan
AE
.
Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura
.
Ann Hematol
.
2016
;
95
(
11
):
1751
-
1756
.
36.
Shortt
J
,
Oh
DH
,
Opat
SS
.
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura
.
N Engl J Med
.
2013
;
368
(
1
):
90
-
92
.
37.
Scully
M
,
Knöbl
P
,
Kentouche
K
, et al
.
Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura
.
Blood
.
2017
;
130
(
19
):
2055
-
2063
.
38.
Plaimauer
B
,
Kremer Hovinga
JA
,
Juno
C
, et al
.
Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies
.
J Thromb Haemost
.
2011
;
9
(
5
):
936
-
944
.
39.
van Balen
T
,
Schreuder
MF
,
de Jong
H
,
van de Kar
NC
.
Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib
.
Eur J Haematol
.
2014
;
92
(
1
):
80
-
82
.
40.
Ratnasingam
S
,
Walker
PA
,
Tran
H
, et al
.
Bortezomib-based antibody depletion for refractory autoimmune hematological diseases
.
Blood Adv
.
2016
;
1
(
1
):
31
-
35
.
You do not currently have access to this content.